Skip to main content
Top
Published in: Medical Microbiology and Immunology 2/2019

01-04-2019 | Cystic Fibrosis | Original Investigation

Secretory IgA-mediated immune response in saliva and early detection of Pseudomonas aeruginosa in the lower airways of pediatric cystic fibrosis patients

Authors: Renan Marrichi Mauch, Claudio Lucio Rossi, Marcos Tadeu Nolasco da Silva, Talita Bianchi Aiello, José Dirceu Ribeiro, Antônio Fernando Ribeiro, Niels Høiby, Carlos Emilio Levy

Published in: Medical Microbiology and Immunology | Issue 2/2019

Login to get access

Abstract

Pseudomonas aeruginosa (Pa) detection in the paranasal sinuses may help to prevent or postpone bacterial aspiration to the lower airways (LAW) and chronic lung infection in cystic fibrosis (CF). We assessed the ability of an ELISA test for measurement of specific Pa secretory IgA (sIgA) in saliva (a potential marker of sinus colonization) to early detect changes in the Pa LAW status (indicated by microbiological sputum or cough swab culture and specific serum IgG levels) of 65 patients for three years, in different investigation scenarios. Increased sIgA levels were detected in saliva up to 22 months before changes in culture/serology. Patients who remained Pa-positive had significantly increased sIgA levels than patients who remained Pa-negative, both at the baseline (39.6 U/mL vs. 19.2 U/mL; p = 0.02) and at the end of the follow-up (119.4 U/mL vs. 25.2 U/mL; p < 0.001). No association was found between sIgA levels in saliva and emergence or recurrence of Pa in the LAW. A positive median sIgA result in the first year of follow-up implied up to 12.5-fold increased risk of subsequent Pa exposure in the LAW. Our test detected early changes in the P. aeruginosa LAW status and risk of exposure to P. aeruginosa in the LAW with two years in advance. Comparison with sinus culture is needed to assess the test’s ability to identify CF patients in need of a sinus approach for Pa investigation, which could provide opportunities of Pa eradication before its aspiration to the lungs.
Literature
15.
go back to reference Gilligan PH, Kiska DL, Appleman MD (2006) Cumitech 43, Cystic fibrosis microbiology. Coordinating editor, Appleman MD. ASM Press, Washington, D.C. Gilligan PH, Kiska DL, Appleman MD (2006) Cumitech 43, Cystic fibrosis microbiology. Coordinating editor, Appleman MD. ASM Press, Washington, D.C.
Metadata
Title
Secretory IgA-mediated immune response in saliva and early detection of Pseudomonas aeruginosa in the lower airways of pediatric cystic fibrosis patients
Authors
Renan Marrichi Mauch
Claudio Lucio Rossi
Marcos Tadeu Nolasco da Silva
Talita Bianchi Aiello
José Dirceu Ribeiro
Antônio Fernando Ribeiro
Niels Høiby
Carlos Emilio Levy
Publication date
01-04-2019
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 2/2019
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-019-00578-w

Other articles of this Issue 2/2019

Medical Microbiology and Immunology 2/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine